BioVie (NASDAQ:BIVI), a clinical-stage biopharma focused on neurological and neurodegenerative diseases, will host a live investor webinar on June 2, 2026 at 4:15 p.m. ET.
Management will discuss bezisterim (NE3107), late-stage drug candidate BIV201, clinical progress, safety data, and upcoming milestones, followed by a Q&A session.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – BIVI
+2.78%
2 alerts
+2.78%Session close to close
$10.71MMarket Cap
1.5xRel. Volume
In the May 27 session, BIVI gained 2.78%, reflecting a moderate positive market reaction.
Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
This announcement highlights an investor webinar where management plans to discuss bezisterim’s role...
Analysis
This announcement highlights an investor webinar where management plans to discuss bezisterim’s role in neurological and neurodegenerative diseases and provide an update on BIV201 for refractory ascites. It follows recent milestones such as Phase 2 completion in Parkinson’s and full enrollment in a Long COVID trial. Investors may focus on how management frames upcoming data readouts, potential partnerships, and the commercial landscape for these late-stage programs as key markers of future progress.
Key Figures
Investor webinar time:June 2, 2026 at 4:15 p.m. ET
1 metrics
Investor webinar timeJune 2, 2026 at 4:15 p.m. ETScheduled BioVie investor webinar hosted by RedChip Companies
SUNRISE-PD abstract accepted for AD/PD 2026 poster presentation.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent BIVI news has generally been positive, with three clinical or scientific updates seeing aligned positive price reactions and two announcements (including the Long COVID trial enrollment) met with negative reactions, indicating occasional sell-the-news dynamics.
Recent Company History
Over the last few months, BioVie has focused on advancing bezisterim and its neurology programs. Key updates included full enrollment of the ADDRESS-LC Phase 2 Long COVID trial on May 26, 2026 and completion of the Phase 2 SUNRISE-PD Parkinson’s study on May 18, 2026. Earlier, abstracts from SUNRISE-PD were accepted for presentation at AAN 2026 and AD/PD 2026. Today’s investor webinar invite fits into this pattern of ongoing clinical and scientific visibility initiatives.
Key Terms
blood-brain barrier, neurodegenerative, neuroinflammation, erk, +4 more
8 terms
blood-brain barriermedical
"oral drug candidate that crosses the blood-brain barrier and works to reduce"
A protective barrier of tightly packed cells and supporting tissue that controls what substances in the blood can enter the brain, acting like a security checkpoint that keeps out most pathogens and many drugs while allowing essential nutrients through. For investors, the barrier matters because whether a therapy can cross or safely bypass it often determines clinical success, regulatory approval and commercial potential for treatments of brain disorders.
neurodegenerativemedical
"developing innovative drug therapies for neurological and neurodegenerative diseases, is pleased"
Neurodegenerative describes diseases where nerve cells in the brain or spinal cord progressively lose function and die, causing worsening movement, memory or other mental abilities over time. For investors this matters because such conditions create large, long-term needs for therapies and caregiving; developing treatments often requires lengthy, expensive research and regulatory testing but can lead to substantial, sustained market opportunities if a therapy proves effective — like fixing the wiring in a whole neighborhood rather than a single house.
Neuroinflammation is the brain or spinal cord’s immune reaction to injury, infection, or abnormalities, where cells and molecules become active to protect or repair nervous tissue. It matters to investors because it underlies many neurological diseases and is a common target for drugs and diagnostic tools; positive or negative trial results, safety signals, or new therapies can change a company’s value much like a major repair plan or recall would affect a carmaker’s prospects.
ERK (extracellular signal‑regulated kinase) is a protein inside cells that acts like a relay station or molecular switch, passing signals that tell cells when to grow, divide, or die. Investors should care because drugs that block or alter ERK activity are central to many cancer and disease treatment strategies; successes or failures in targeting ERK can strongly affect a drug candidate's clinical prospects, regulatory outlook, and a biotech company's valuation.
nfκb is a protein complex that acts like a master switch inside cells, turning on genes that drive inflammation, immune responses and cell survival when the body senses stress or infection. Investors care because many therapies, diagnostics and safety assessments target or measure this switch; changes in nfκb activity can indicate potential drug opportunities, predict side‑effect risks, or serve as a biomarker that affects a drug candidate’s development value.
Tumor necrosis factor alpha (TNF-α) is a naturally produced signaling protein that prompts and sustains inflammation in the body; think of it as a smoke alarm that can trigger a large immune response. Investors care because many drugs aim to block or measure TNF-α to treat inflammatory diseases, so changes in clinical trial results, regulatory decisions, or diagnostic use tied to TNF-α can materially affect the value of companies developing those therapies.
orphan drugregulatory
"outline progress with BIV201, BioVie’s late-stage orphan drug candidate for refractory"
A drug designated for an orphan disease is a medicine developed to treat a rare condition that affects only a small number of people. Regulators often give these drugs special incentives—such as reduced costs, faster review, and temporary exclusive selling rights—to encourage development, which matters to investors because those incentives can make a small market financially viable and reduce competition, much like a temporary patent on a niche product.
refractory ascitesmedical
"orphan drug candidate for refractory ascites, a life-threatening complication of liver"
Refractory ascites is the buildup of excess fluid in the abdomen that does not go away with standard treatments such as fluid restriction and medicines that remove excess water. It matters to investors because it signals advanced, hard-to-treat disease that can drive demand for new therapies, affect clinical trial results and regulatory decisions, and influence the commercial prospects and valuation of companies working on treatment or management options.
CARSON CITY, Nev., May 27, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, is pleased to invite investors to a webinar on June 2, 2026, at 4:15 p.m. ET.
The exclusive event, hosted by RedChip Companies, will feature Cuong Do, President and CEO of BioVie, who will discuss bezisterim (NE3107), the Company’s investigational oral drug candidate that crosses the blood-brain barrier and works to reduce inflammation and improve insulin sensitivity without suppressing the immune system and with a low risk of drug-drug interactions. By modulating key pathways involved in neuroinflammation (ERK, NFκB, TNF-α), bezisterim may have therapeutic potential in several disease indications, including Parkinson’s disease, Long COVID, and Alzheimer’s disease. He will also outline progress with BIV201, BioVie’s late-stage orphan drug candidate for refractory ascites, a life-threatening complication of liver cirrhosis with no FDA-approved therapies. With multiple late-stage clinical programs advancing, strong safety data, and multi-billion-dollar market opportunities, BioVie is positioned to deliver significant value creation as it approaches pivotal milestones and potential partnerships.
A live Q&A session with management will follow the presentation.
Questions can be pre-submitted to BIVI@redchip.com or asked online during the live event.
About BioVie, Inc.
BioVie Inc. (NASDAQ: BIVI) is a clinical-stage biopharmaceutical company focused on developing therapies for neurological disorders and advanced liver disease. Its lead candidate, bezisterim (NE3107), targets neuroinflammation and insulin resistance, which are believed to be key drivers of Alzheimer’s and Parkinson’s disease. Bezisterim is also being studied for long COVID, where persistent inflammation is thought to underlie symptoms such as brain fog and fatigue.
In liver disease, BioVie is advancing BIV201, a continuous infusion of terlipressin treatment that has received FDA Orphan and Fast Track designations. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis, and the Company plans to study BIV201 in a Phase 3 trial for the reduction of further decompensation in patients with cirrhosis and ascites. For more information, visit www.bioviepharma.com.
Forward-Looking Statements
This press release contains forward-looking statements, which may be identified by words such as "expect," "look forward to," "anticipate" "intend," "plan," "believe," "seek," "estimate," "will," "project" or words of similar meaning. Although BioVie Inc. believes such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Actual results may vary materially from those expressed or implied by the statements herein due to the Company's ability to successfully raise sufficient capital on reasonable terms or at all, available cash on hand and contractual and statutory limitations that could impair our ability to pay future dividends, our ability to complete our pre-clinical or clinical studies and to obtain approval for our product candidates, our ability to successfully defend potential future litigation, changes in local or national economic conditions as well as various additional risks, many of which are now unknown and generally out of the Company's control, and which are detailed from time to time in reports filed by the Company with the SEC, including quarterly reports on Form 10-Q, reports on Form 8-K and annual reports on Form 10-K. BioVie Inc. does not undertake any duty to update any statements contained herein (including any forward-looking statements), except as required by law.
Contact: Dave Gentry RedChip Companies, Inc. 1-407-644-4256 BIVI@redchip.com
When is the BioVie (NASDAQ:BIVI) live investor webinar on June 2, 2026?
The BioVie investor webinar is scheduled for June 2, 2026, at 4:15 p.m. ET. According to BioVie, the event will feature management presentations on key drug candidates and a live Q&A session for investors.
How can investors register for the June 2, 2026 BioVie (BIVI) webinar?
Investors can register for the free BioVie webinar by visiting the RedChip registration link provided by the company. According to BioVie, attendees may also submit questions in advance via email or ask them live during the event.
What will BioVie (BIVI) present about bezisterim (NE3107) during the investor webinar?
BioVie plans to discuss bezisterim (NE3107), its investigational oral drug candidate targeting neuroinflammation and insulin sensitivity. According to BioVie, bezisterim crosses the blood-brain barrier and may have potential in Parkinson’s disease, Long COVID, and Alzheimer’s disease by modulating ERK, NFκB, and TNF-α pathways.
What is BioVie’s BIV201 program and will it be covered in the June 2026 webinar?
Yes, BioVie’s BIV201 program will be discussed during the webinar. According to BioVie, BIV201 is a late-stage orphan drug candidate for refractory ascites, a life-threatening complication of liver cirrhosis that currently has no FDA-approved therapies.
Who will speak at the June 2, 2026 BioVie (NASDAQ:BIVI) investor webinar?
Cuong Do, BioVie’s President and CEO, will lead the presentation. According to BioVie, he will review the bezisterim and BIV201 programs, highlight late-stage clinical progress, discuss safety data, market opportunities, and outline upcoming milestones and potential partnerships.
What topics of interest to BioVie (BIVI) shareholders will be covered in the webinar Q&A?
The live Q&A will allow investors to ask questions directly to BioVie’s management. According to BioVie, questions can address clinical programs, market opportunities, upcoming milestones, and overall strategy, and may be submitted in advance or during the live online session.
